A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have ...
How is it possible to spend tens of billions of dollars developing drugs to treat a serious disease that affects millions of ...
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, ...
Morning Overview on MSN
Major review finds new Alzheimer’s drugs offer no meaningful patient benefit
For the millions of families watching a loved one slip away to Alzheimer’s disease, the arrival of drugs that promised to ...
Seventeen placebo-controlled trials across seven antibodies yielded statistically significant but clinically small mean ...
Anti-amyloid drugs likely provide no "clinically meaningful" effects for people with Alzheimer's, the authors concluded.
Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.
Scientists from Johns Hopkins Medicine report new evidence that clusters of brain tissue derived from the cells of patients ...
CLEVELAND, Ohio — Case Western Reserve University researchers have received a $6.2 million grant to identify new genetic ...
Some common medications have been connected to a lower risk of dementia, but the challenge for scientists is to discern ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results